Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Hematopoietic Cell Transplantation, Version 3.2022. Journal of the National Comprehensive Cancer Network : JNCCN Saad, A., Loren, A., Bolanos-Meade, J., Chen, G., Couriel, D., Di Stasi, A., El-Jawahri, A., Elmariah, H., Farag, S., Gundabolu, K., Gutman, J., Ho, V., Hoeg, R., Horwitz, M., Hsu, J., Kassim, A., Kharfan Dabaja, M., Magenau, J., Martin, T., Mielcarek, M., Moreira, J., Nakamura, R., Nieto, Y., Ninos, C., Oliai, C., Patel, S., Randolph, B., Schroeder, M., Tzachanis, D., Varshavsky-Yanovsky, A. N., Vusirikala, M., Algieri, F., Pluchino, L. A. 2023; 21 (2): 108-115

Abstract

The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease-a major complication of allogeneic HCT-to enable the patient and clinician to assess management options in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.

View details for DOI 10.6004/jnccn.2023.0007

View details for PubMedID 36791762